

## \$6.6 million Placement to advance clinical trial pipeline

- Capital raising strongly supported by institutional, sophisticated, and professional investors, with investor allocations scaled back due to excess demand
- Cornerstone support from a US-based family office
- Funds will primarily support advancement of CHM CDH17
- Placement comprises two tranches at an issue price of \$0.004 per share
- Options with piggyback right provide potential for the Company to raise significant additional capital
- With the funds raised, Chimeric intends to terminate the Placement Agreement with Lind Global Fund II, LP (see ASX announcement 23 June 2023)

**Melbourne, Australia, 20 May 2025:** Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”, is pleased to announce it has received firm commitments to raise \$6.6 million (before costs) through a two-tranche placement to institutional, sophisticated, and professional investors (Placement Subscribers), with cornerstone support from a US-based family office.

The Placement will issue approximately 1.65 billion new fully paid ordinary shares (Placement Shares) at \$0.004 per share, together with 1.65 billion 1-for-1 unlisted options exercisable at \$0.004, expiring 8 months from issuance (Attaching Option). Each option exercised within 5 months of issue will trigger an additional option (up to 1.65 billion) exercisable at \$0.005, expiring 8 months from issuance (Contingent Option).

The Placement price represents a 50% discount to the last traded price of \$0.008 and a 44% discount to the 15-day volume-weighted average price (VWAP) of \$0.0072.

Tranche 1 comprises approximately 164.3 million shares (~\$0.657 million), issued under the Company’s existing ASX Listing Rule 7.1 placement capacity. The allotment is expected to occur on Monday 26 May 2025, with normal trading of the Tranche 1 shares commencing shortly thereafter.

Tranche 2, consisting of approximately 1.49 billion shares (~\$5.943 million), including the attaching options, is subject to shareholder approval at an extraordinary general meeting (EGM), anticipated to be held in July 2025.



PAC Partners Securities Pty Ltd and Taylor Collison Limited acted as Joint Lead Managers for the Placement who, subject to shareholder approval, will be issued 25 million Adviser Options on account of professional services provided to the Company.

Use of Funds: Proceeds from the Placement will be directed towards:

- CHM CDH17 CAR-T clinical trial – advancing to dose level 2 with promising early clinical signals and strong patient recruitment.
- CORE-NK clinical trials – progressing Phase 1B trials demonstrating encouraging preliminary efficacy in acute myeloid leukemia (AML).
- General working capital and costs associated with the capital raising.

In conjunction with the capital raising, the Company has notified Lind Global Fund II, LP (Lind) of the Company's intent to exercise its right to terminate the Placement Agreement (Agreement) with Lind announced on 23 June 2023, effective immediately in accordance with the terms set out in that announcement.

Dr Rebecca McQualter, Chimeric Therapeutics' Chief Executive Officer, commented: "We are very pleased with the strong response from investors, having raised substantially more than initially targeted. This support highlights the market's confidence in our cell therapy programs and strengthens our position to accelerate our promising programs towards further key clinical milestones."

## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.



CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper

### **Contact**

#### Investors

Dr Rebecca McQualter  
Chief Executive Officer  
Chimeric Therapeutics  
E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

#### Media

Matthew Wright  
NWR Communications  
T: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## Attaching Option terms

<b>Eligibility</b>	Attaching Options to be issued to Placement Subscribers who subscribe for Placement Shares under the Placement Offer.
<b>Grant of Attaching Options</b>	To be issued on the basis of one Attaching Option for every one Placement Share issued to Placement Subscribers.
<b>Quotation of Attaching Options</b>	The Company will not apply to ASX for official quotation of the Attaching Options.
<b>Exercise of Options</b>	<p>Each Attaching Option is exercisable immediately on issue. The Attaching Options may be exercised at any time before their expiry date, wholly or in part, by delivering a duly completed form of notice of exercise together with a cheque for the exercise price. The Company will issue one Share for each Attaching Option exercised.</p> <p>Holders of Attaching Options may only exercise a minimum of \$1,000 of Attaching Options on any particular occasion, unless the Holder has, in total, less than \$1,000 of Attaching Options, in which case they must exercise all their Attaching Options at the same time.</p> <p>The exercise of each Attaching Option is subject to compliance with the <i>Corporations Act 2001</i> (Cth) (<b>Corporations Act</b>) (in particular, the requirements of Chapter 6 of the Corporations Act).</p> <p>Upon receiving a valid Attaching Options exercise notice, the Company must issue the number of Shares equal to the number of Attaching Options the subject of the valid Attaching Options exercise notice as soon as reasonably practicable. If the exercise notice is served by the option holder within five months from the date of the issue of the Attaching Options, the Company must also issue the number of Contingent Options the subject of the valid Attaching Options exercise notice.</p>
<b>Terms of Shares issued</b>	Any Shares issued as a result of exercising an Attaching Option will be issued on the same terms and rank in all respects on equal terms, with existing Shares.
<b>Transfer and security interests</b>	<p>Placement Subscribers may only:</p> <p>(a) create a security interest in; or</p> <p>(b) transfer, assign, dispose or otherwise deal with,</p> <p>Attaching Options, or any interest in Attaching Options, with the prior written consent of the Board.</p>
<b>Quotation of Shares issued</b>	Application for official quotation of Shares allotted and issued as a result of the exercise of the Attaching Options will be within five business days from the date of issue of the Shares.
<b>Expiration of Attaching Options</b>	Each Attaching Option will have an expiration date that is approximately 8 months from the date of issue of the Attaching Options.
<b>Issue price of Attaching Options</b>	No issue price is payable for the Attaching Options as they are issued together with any application by a Placement Subscriber for Placement Shares.
<b>Exercise price of Attaching Options</b>	\$0.004 upon exercise to acquire each Share.

<b>Option register</b>	Attaching Options will be registered in the name of a Shareholder in an option register maintained by the Company's share registry. The share registry will issue holding statements that evidence the number of Attaching Options held by the Placement Subscribers. No option certificates will be issued.
<b>Reconstruction of capital</b>	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company: <ul style="list-style-type: none"> <li>(a) the number of Attaching Options or the exercise price of the Attaching Options or both will be adjusted as specified in Listing Rule 7.22 as it applies at the time of the reorganisation; and</li> <li>(b) in all other respects the terms for the exercise of the Attaching Options will remain unchanged.</li> </ul>
<b>Adjustment where pro rata issue of Shares, bonus shares or stock dividends</b>	There will be no adjustment to the terms of the Attaching Options if there is a pro rata issue of Shares.
<b>New issues of Shares</b>	The Attaching Options do not confer a right to participate in new issues of Shares unless the Attaching Options have been exercised on or before the record date for determining entitlements to the issue.
<b>Notice of adjustments</b>	The Company will give written notice to the Attaching Option holder of any adjustment of the exercise price of the Attaching Options and any increase or decrease in the number of Attaching Options.
<b>Dividend rights</b>	While they remain unexercised, the Attaching Options will not give a holder an entitlement to receive any dividends declared and paid by the Company for Shares.
<b>Applicable law</b>	Each Attaching Option is issued subject to: <ul style="list-style-type: none"> <li>(a) the Corporations Act;</li> <li>(b) the Listing Rules; and</li> <li>(c) the Company's constitution.</li> </ul>
<b>US securities law restriction</b>	The Attaching Options may not be exercised by or on behalf of a person in the United States unless the Attaching Options and the underlying shares have been registered under the <i>US Securities Act of 1933</i> and applicable US state securities laws, or exemptions from such registration requirements are available.

## Contingent Option terms

<b>Eligibility</b>	Contingent Options to be issued to Placement Subscribers who have elected to exercise the Attaching Options within five months from the date of the issue of the Attaching Options.
<b>Grant of Contingent Options</b>	To be issued on the basis of one Contingent Option for every one Attaching Option exercised within five months from the date of the issue of the Attaching Options.
<b>Quotation of Attaching Options</b>	The Company will not apply to ASX for official quotation of the Contingent Options.
<b>Exercise of Options</b>	<p>Each Contingent Option is exercisable immediately on issue. The Contingent Options may be exercised at any time before their expiry date, wholly or in part, by delivering a duly completed form of notice of exercise together with a cheque for the exercise price. The Company will issue one Share for each Contingent Option exercised.</p> <p>Holders of Contingent Options may only exercise a minimum of \$1,000 of Contingent Options on any particular occasion, unless the Holder has, in total, less than \$1,000 of Contingent Options, in which case they must exercise all their Contingent Options at the same time.</p> <p>The exercise of each Contingent Option is subject to compliance with the <i>Corporations Act 2001</i> (Cth) (<b>Corporations Act</b>) (in particular, the requirements of Chapter 6 of the Corporations Act).</p> <p>Upon receiving a valid Contingent Options exercise notice, the Company must issue the number of Shares equal to the number of Contingent Options the subject of the valid Contingent Options exercise notice as soon as reasonably practicable.</p>
<b>Terms of Shares issued</b>	Any Shares issued as a result of exercising a Contingent Option will be issued on the same terms and rank in all respects on equal terms, with existing Shares.
<b>Transfer and security interests</b>	<p>Placement Subscribers may only:</p> <ul style="list-style-type: none"> <li>(a) create a security interest in; or</li> <li>(b) transfer, assign, dispose or otherwise deal with,</li> </ul> <p>Contingent Options, or any interest in Contingent Options, with the prior written consent of the Board.</p>
<b>Quotation of Shares issued</b>	Application for official quotation of Shares allotted and issued as a result of the exercise of the Contingent Options will be within five business days from the date of issue of the Shares.
<b>Expiration of Contingent Options</b>	Each Contingent Option will have an expiration date that is approximately 8 months from the date of issue of the Contingent Options.
<b>Issue price of Contingent Options</b>	No issue price is payable for the Contingent Options.
<b>Exercise price of Contingent Options</b>	\$0.005 upon exercise to acquire each Share.

<b>Option register</b>	Contingent Options will be registered in the name of a Shareholder in an option register maintained by the Company's share registry. The share registry will issue holding statements that evidence the number of Contingent Options held by the Placement Subscribers. No option certificates will be issued.
<b>Reconstruction of capital</b>	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of the Company: <ul style="list-style-type: none"> <li>(a) the number of Contingent Options or the exercise price of the Contingent Options or both will be adjusted as specified in Listing Rule 7.22 as it applies at the time of the reorganisation; and</li> <li>(b) in all other respects the terms for the exercise of the Contingent Options will remain unchanged.</li> </ul>
<b>Adjustment where pro rata issue of Shares, bonus shares or stock dividends</b>	There will be no adjustment to the terms of the Contingent Options if there is a pro rata issue of Shares.
<b>New issues of Shares</b>	The Contingent Options do not confer a right to participate in new issues of Shares unless the Contingent Options have been exercised on or before the record date for determining entitlements to the issue.
<b>Notice of adjustments</b>	The Company will give written notice to the Contingent Option holder of any adjustment of the exercise price of the Contingent Options and any increase or decrease in the number of Contingent Options.
<b>Dividend rights</b>	While they remain unexercised, the Contingent Options will not give a holder an entitlement to receive any dividends declared and paid by the Company for Shares.
<b>Applicable law</b>	Each Contingent Option is issued subject to: <ul style="list-style-type: none"> <li>(a) the Corporations Act;</li> <li>(b) the Listing Rules; and</li> <li>(c) the Company's constitution.</li> </ul>
<b>US securities law restriction</b>	The Contingent Options may not be exercised by or on behalf of a person in the United States unless the Contingent Options and the underlying shares have been registered under the <i>US Securities Act of 1933</i> and applicable US state securities laws, or exemptions from such registration requirements are available.